CancerFax Establishes Strategic Partnership with RoyalLee Cancer Hospital in Guangzhou

CancerFax has formally partnered with RoyalLee Cancer Hospital in Guangzhou, China, creating a new pathway for international patients to access advanced cancer treatments in one of China's most dynamic medical and innovation zones.

The partnership was signed on January 14, 2026, during a visit by Sandeep Kumar Wamne, Founder of CancerFax, to the hospital's facilities in the Sino-Singapore Guangzhou Knowledge City (SSGKC), Huangpu District, Guangzhou.

Why This Partnership Matters

For cancer patients outside China, finding and accessing the right hospital can be genuinely difficult. Treatment landscapes differ. Language barriers are real. Coordinating records, appointments, and logistics from another country is often overwhelming.

This partnership addresses that gap directly. It gives CancerFax a formal collaboration framework with RoyalLee Cancer Hospital, allowing the CancerFax team to support international patients in connecting with the hospital's specialists, treatment programs, and advanced clinical capabilities.

RoyalLee Cancer Hospital is located within the Sino-Singapore Guangzhou Knowledge City, a national-level bilateral cooperation zone between China and Singapore. The zone is designed to bring together research, innovation, and healthcare at an international level, making it a strategically important site for advanced oncology programs and cross-border medical collaboration.

About the Visit and Signing

Professor Li Dinggang, Chief International Medical Consultant at RoyalLee Hospital, facilitated the visit. Sandeep Kumar Wamne was received by Ms. Ma Lanying, Vice President and Head of International Medical Services, and Mr. Liang Bing, Honorary Vice President.

During the visit, the CancerFax team toured key departments including the Health Examination Center, Nuclear Medicine Department, Operating Rooms, International Ward, and VIP Ward, and held detailed discussions on:

• Cross-border cancer diagnosis and treatment collaboration
• Integration of international medical resources
• Whole-process patient support services
• International medical referral pathways and information sharing

A formal cooperation agreement was signed at the conclusion of the visit.

What RoyalLee Cancer Hospital Offers

RoyalLee Cancer Hospital brings a strong set of clinical capabilities, with particular depth in minimally invasive and interventional oncology. According to Professor Li Dinggang, the hospital's focus is on bringing innovative therapies, precision systems, and experienced clinical teams to patients with complex and advanced cancers.

Key treatment capabilities include:

Yttrium-90 (Y-90) Selective Internal Radiation Therapy Y-90 is a radioembolization technique used primarily for liver cancers and liver metastases. Tiny radioactive beads are delivered through a catheter directly to the blood vessels supplying the tumor, delivering targeted radiation while minimizing exposure to surrounding healthy tissue. It may be considered in patients with unresectable liver cancer, hepatocellular carcinoma, or liver-dominant metastatic disease, subject to eligibility assessment.

Argon-Helium Cryoablation This technique uses extreme cold to freeze and destroy tumor tissue. It can be used in carefully selected patients with solid tumors, including lung, liver, kidney, and other cancers, as a minimally invasive option when surgery is not appropriate. Eligibility depends on tumor size, location, and patient condition.

Nanoknife (Irreversible Electroporation) Nanoknife is a non-thermal ablation technology that uses electrical pulses to destroy cancer cells. It is particularly relevant for tumors near critical structures such as blood vessels or bile ducts, where heat-based or cold-based ablation may carry higher risk. It is used in selected patients with pancreatic, liver, and other difficult-to-access cancers.

Beyond these interventional technologies, the hospital has advanced infrastructure including nuclear medicine facilities, multidisciplinary collaboration programs, rigorous quality management, and a dedicated international ward designed to support patients traveling from abroad.

What This Means for International Patients

For patients in India, Southeast Asia, the Middle East, Africa, and other regions where access to interventional oncology at this level is limited, this partnership opens a more structured pathway to evaluate whether treatment at RoyalLee may be relevant to their situation.

The CancerFax team can now assist patients in several ways:

• Reviewing medical reports to understand whether RoyalLee's capabilities match the patient's diagnosis and stage
• Communicating with the hospital's International Medical Center on behalf of patients
• Coordinating second opinions and treatment plan reviews with the oncology team
• Supporting practical logistics including documentation, appointment planning, and travel guidance
• Maintaining continuity of information between the patient, their local oncologist, and the treating team in China

It is important to note that suitability for any of these treatments requires thorough medical evaluation. A history, imaging review, pathology report, and specialist consultation are needed before any treatment recommendation can be made. CancerFax facilitates access to that evaluation process, not the outcome itself.

Greater Bay Area: A Growing Oncology Destination

The Guangdong-Hong Kong-Macao Greater Bay Area has emerged as one of the most significant zones for advanced healthcare and biomedical research in China. Guangzhou in particular has invested heavily in building a high-end healthcare and biopharmaceutical ecosystem.

For international patients, this matters because the density of advanced clinical capabilities, research programs, and specialized centers in this region is significant. RoyalLee's location within the Sino-Singapore Guangzhou Knowledge City places it at the center of this development, with access to cutting-edge infrastructure and a growing network of international cooperation programs.

Shared Commitment to Patient-Centered Care

What stood out in our discussions with the RoyalLee team was a shared value that drives both organizations: the belief that patients with advanced cancer deserve access to the full range of clinical options available to them, regardless of where they live.

Professor Li Dinggang expressed it plainly: "Only innovative therapies, systems, and teams can bring hope to patients with advanced cancer. We hope to establish a professional platform to make richer and better treatment options accessible to more international patients."

This resonates directly with why CancerFax exists. Too many patients are still making treatment decisions based on what is locally available, without knowing what else may be possible. This partnership is one more way CancerFax is working to change that.

How CancerFax Can Help

If you or someone you care for is dealing with a complex cancer diagnosis and would like to understand whether treatment at RoyalLee Cancer Hospital may be relevant, CancerFax can help you take the next step.

We work with patients to review their medical records, identify appropriate hospitals and specialists, coordinate case discussions, and manage the practical aspects of pursuing care in China. Our team communicates in English and supports patients through each stage of the process.

You can reach the CancerFax team by emailing [email protected] or through WhatsApp at +86 182 1759 2149.

Frequently Asked Questions

What is RoyalLee Cancer Hospital and where is it located? RoyalLee Cancer Hospital is located in the Sino-Singapore Guangzhou Knowledge City in Huangpu District, Guangzhou, China. It is a specialized cancer hospital with a focus on advanced minimally invasive and interventional oncology treatments, as well as multidisciplinary cancer care.

What types of cancer treatments does RoyalLee offer for international patients? RoyalLee has strong capabilities in interventional oncology including Yttrium-90 selective internal radiation therapy, argon-helium cryoablation, and nanoknife (irreversible electroporation) technology. The hospital also has nuclear medicine facilities, operating rooms, and a dedicated international ward. Suitability for any treatment depends on cancer type, stage, and individual patient evaluation.

How can CancerFax help me access treatment at RoyalLee? CancerFax can review your medical reports, assess whether RoyalLee's capabilities match your diagnosis, coordinate communication with the hospital's International Medical Center, help plan the logistics of your visit, and support you through the process of obtaining a second opinion or beginning treatment.

Is this partnership relevant for patients with liver cancer or liver metastases? The hospital's Y-90 and ablation capabilities are particularly relevant for patients with liver cancers or liver-dominant metastatic disease. However, eligibility depends on individual factors including tumor burden, liver function, prior treatment history, and overall performance status. A proper medical evaluation is essential.

Do I need to travel to China to benefit from this partnership? An initial case review can often be done remotely. CancerFax can help facilitate a preliminary assessment of your records with the RoyalLee team before any decision about travel is made. For actual treatment, most patients would need to travel to Guangzhou.

How do I contact CancerFax to explore this option? You can email [email protected] or message the CancerFax team on WhatsApp at +86 182 1759 2149. Sharing your recent medical reports, pathology results, and imaging reports will help the team provide an informed initial response.